| Old Articles: <Older 8581-8590 Newer> |
|---|
 |
Chemistry World
February 27, 2013
Andrew Turley |
Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.   |
Chemistry World
February 27, 2013
Anthony King |
PharmaSea to scour ocean depths for new drugs A new project will soon see scientists trawling the ocean bottoms for new bioactive compounds. Scientists on the PharmaSea mission will haul samples of mud and sediment from the deep sea, isolating marine organisms in the hunt for novel drug candidates. |
Chemistry World
February 21, 2013
Andrew Turley |
$595m octreotide deal grabs Roche Swiss drugmaker Roche has struck a $595 million deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth |
Chemistry World
February 19, 2013
Andrew Turley |
Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin). |
Chemistry World
February 14, 2013
Andrew Turley |
BMS sells OTC drugs for $482m UK consumer goods giant Reckitt Benckiser has struck a $482 million deal to buy from Bristol-Myers Squibb rights to a range of over-the-counter drugs in parts of Latin America, including Brazil and Mexico. |
Chemistry World
February 14, 2013
Patrick Walter |
Drugs to blame for anti-social fish Swedish scientists say that low levels of psychotherapeutic drugs can change the way fish behave and could be altering the balance of entire aquatic food webs. |
Pharmaceutical Executive
February 1, 2013
Julian Upton |
Turkey: A Promise Restored? After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. |
Pharmaceutical Executive
February 1, 2013
Stan Bernard |
Why Product Lifecycle Management Fails Pharma: Time for a Rethink? Pharma professionals adopting the "Drug Life Optimization" approach can wrest more value through strategies that build and promote a drug's brand franchise through its entire lifespan, not simply the product lifecycle. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive
February 1, 2013 |
Country Report: Australia In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally. |
| <Older 8581-8590 Newer> Return to current articles. |
